Sentinel NOSE: Prospective feasibility study on sentinel lymph node biopsy in bulky nasal vestibule cancer
PLOS One · 2025
DOI: 10.1371/journal.pone.0325764 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Michal D Czerwinski und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Sentinel Lymph Node Biopsy, Nose Neoplasms, Carcinoma, Squamous Cell, Sentinel Lymph Node. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Patients with bulky squamous cell carcinoma of the nasal vestibule are at high risk of nodal relapse and have worse prognosis, despite modern neck imaging. More sensitive assessment of the neck may obviate elective treatment and ultimately reduce the risk of nodal relapse and improve outcome. The goal of this study was to evaluate the feasibility, safety and tolerability of sentinel lymph node biopsy (SLNB) in staging of bulky squamous cell nasal vestibule carcinoma (NVC).
Methods
Ten patients with cT1-T2N0 squamous cell NVC with diameter ≥1.5 cm, planned for curative brachytherapy, were prospectively included to undergo four peritumoral injections of ICG-[ 99m Tc]Tc-nanocolloid. Subsequently, dynamic, static and SPECT/CT images were performed. The following day SLNB was conducted under general anesthesia combined with brachytherapy implantation of the primary tumor.
Results
Sentinel lymph nodes were visualized in all patients (median 3.5 per patient), with successful subsequent biopsy in all cases (median yield 2.5 per patient). Occult lymph node metastases were found in 50% of patients. The procedure was well-tolerated.
Conclusion
SLNB in bulky NVC is feasible and safe, with a high success rate of executing the SLN procedure. The relatively high incidence of occult metastases in this population is consistent with earlier findings. Further research is needed to quantify the impact of SLNB in terms of total treatment burden and oncological outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Otorhinolaryngology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Oral and Maxillofacial Surgery, Radboud University Medical Center, Nijmegen, The Netherlands.
ORCID-Profile: Michal D Czerwinski, Anne I J Arens
Zitieren
APA
Czerwinski, M. D., Zwijnenburg, E. M., Arens, A. I. J., Van Engen, A. C. H., Honings, J., Weijs, W. L. J., Takes, R. P., Kaanders, J. H. A. M., & Verhoef, C. G. (2025). Sentinel NOSE: Prospective feasibility study on sentinel lymph node biopsy in bulky nasal vestibule cancer. PLOS One. https://doi.org/10.1371/journal.pone.0325764
Vancouver
Czerwinski MD, Zwijnenburg EM, Arens AIJ, Van Engen ACH, Honings J, Weijs WLJ, et al. Sentinel NOSE: Prospective feasibility study on sentinel lymph node biopsy in bulky nasal vestibule cancer. PLOS One. 2025. doi:10.1371/journal.pone.0325764
BibTeX
@article{Czerwinski2025,
author = {Czerwinski, Michal D and Zwijnenburg, Ellen M and Arens, Anne I J and Van Engen, Adriana C H and Honings, Jimmie and Weijs, Willem L J and Takes, Robert P and Kaanders, Johannes H A M and Verhoef, Cornelia G},
title = {Sentinel NOSE: Prospective feasibility study on sentinel lymph node biopsy in bulky nasal vestibule cancer},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0325764}
}
EUVIMED